SEC Tracker
Get the app
Person · CIK 1835966

Alan B. Sandler

Chief Development Officer at Revolution Medicines; Chief Medical Officer at Alx Oncology Holdings; director at Elevation Oncology

Earlier: Mirati Therapeutics and Zai Lab

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$1.3M
Noticed on Form 144$1.3M
Bought on Form 4$0
Companies5

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Revolution Medicines RVMDCommon StockDirectly52,559Sep 29, 2026 · Filing · EDGAR
Revolution Medicines RVMDStock Option (Right to Buy)
exercise $58.84, expires Nov 1, 2035, into Common Stock
Directly161,300Sep 29, 2026 · Filing · EDGAR
Alx Oncology Holdings ALXOStock option (right to buy)
exercise $1.32, expires Jan 19, 2036, into Common Stock
Directly10,100Jan 20, 2026 · Filing · EDGAR
Zai LabAmerican Depositary SharesDirectly28,985Apr 1, 2022 · Filing · EDGAR
Zai LabOrdinary SharesDirectly27,925Dec 1, 2021 · Filing · EDGAR
Zai LabRestricted Share Units
into American Depositary Shares
Directly73,000Jun 25, 2022 · Filing · EDGAR

Sold and noticed by quarter

Alan B. Sandler: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2025 to Q4 2026$1.3M$0Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $1.3M noticed on Form 144Q3 2026: $1.3M sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q3 2026$1.3M$1.3M

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jun 30, 2026 · 1 notice
Sep 29, 20266,309 · ~$1.3MSep 29, 2026Partly sold Sold 6,008 in 4 sales, Sep 29 to Sep 29 · $1.2M likely match Form 4Filing · EDGAR
Revolution Medicines RVMD · Etrade Financial · No 10b5-1 plan stated · 1 notice
Sep 15, 2026331 · ~$67KSep 15, 2026Partly sold Sold 306 in 2 sales, Sep 16 to Sep 29 · $63K likely match Form 4 (1) · Form 4 (2)Filing · EDGAR
Sales without a matching Form 144 · 1 sale
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Revolution Medicines (RVMD): Sold 336 at $199.30 on Sep 16, 2026 · $67K (10b5-1 plan)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Revolution Medicines RVMD Chief Development Officer · filings 2026 to 2026 · sold $1.3M · $1.3M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Sep 29, 2026Option or RSU exercised or converted+6,000$58.84$353K58,868 directFiling · EDGAR
Sep 29, 2026Sale under a 10b5-1 plan−2,200$200.82$442K56,668 directFiling · EDGAR
Sep 29, 2026Sale under a 10b5-1 plan−1,609$201.72$325K55,059 directFiling · EDGAR
Sep 29, 2026Sale under a 10b5-1 plan−1,000$202.81$203K54,059 directFiling · EDGAR
Sep 29, 2026Sale under a 10b5-1 plan−1,199$203.91$244K52,860 directFiling · EDGAR
Sep 29, 2026Sale under a 10b5-1 plan−301$204.72$62K52,559 directFiling · EDGAR
Sep 29, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−6,000161,300 directFiling · EDGAR
Sep 16, 2026Sale under a 10b5-1 plan−5$194.96$97553,204 directFiling · EDGAR
Sep 16, 2026Sale under a 10b5-1 plan−336$199.30$67K52,868 directFiling · EDGAR

Alx Oncology Holdings ALXO Chief Medical Officer · filings 2024 to 2026

DateTransactionSharesPriceValueHeld afterSource
Jan 20, 2026Grant or award from the company
Stock option (right to buy)
+10,10010,100 directFiling · EDGAR
Apr 11, 2025Grant or award from the company
Employee Stock Option (right to buy)
+125,000125,000 directFiling · EDGAR
Jan 21, 2025Grant or award from the company
Employee Stock Option (right to buy)
+100,000100,000 directFiling · EDGAR
Nov 18, 2024Grant or award from the company
Employee Stock Option (right to buy)
+600,000600,000 directFiling · EDGAR
Aug 5, 2024Grant or award from the company
Stock Option (right to buy)
+40,40040,400 directFiling · EDGAR

Elevation Oncology ELEV Director · filings 2024 to 2025

DateTransactionSharesPriceValueHeld afterSource
Jul 23, 2025Returned to the company
Stock Option (Right to Buy)
−55,0000 directFiling · EDGAR
Jul 23, 2025Returned to the company
Stock Option (Right to Buy)
−35,0000 directFiling · EDGAR
Jul 23, 2025Returned to the company
Stock Option (Right to Buy)
−35,0000 directFiling · EDGAR
Jun 5, 2025Grant or award from the company
Stock Option (Right to Buy)
+35,00035,000 directFiling · EDGAR
Jun 13, 2024Grant or award from the company
Stock Option (Right to Buy)
+35,00035,000 directFiling · EDGAR
Feb 29, 2024Grant or award from the company
Stock Option (Right to Buy)
+55,00055,000 directFiling · EDGAR

Mirati Therapeutics Chief Medical Officer · filings 2022 to 2024

DateTransactionSharesPriceValueHeld afterSource
Jan 23, 2024Returned to the company−10,547$58.00$612K69,318 directFiling · EDGAR
Jan 23, 2024Returned to the company−52,29717,021 directFiling · EDGAR
Jan 23, 2024Returned to the company−17,0210 directFiling · EDGAR
Jan 23, 2024Returned to the company
Option to Purchase Common Stock
−65,0000 directFiling · EDGAR
Dec 29, 2023Grant or award from the company+17,021$58.75$1M79,318 directFiling · EDGAR
Aug 9, 2023Grant or award from the company+22,297$37.00$825K62,297 directFiling · EDGAR
Nov 7, 2022Grant or award from the company+40,00040,000 directFiling · EDGAR
Nov 7, 2022Grant or award from the company
Stock Option (Right to buy)
+65,00065,000 directFiling · EDGAR

Zai Lab Head of Global Dev., Oncology · filings 2021 to 2022

DateTransactionSharesPriceValueHeld afterSource
Jun 25, 2022Grant or award from the company
Restricted Share Units
+73,00073,000 directFiling · EDGAR
Apr 1, 2022Option or RSU exercised or converted+1,06028,985 directFiling · EDGAR
Apr 1, 2022Grant or award from the company
Stock Options (Right to Buy)
+87,69987,699 directFiling · EDGAR
Apr 1, 2022Grant or award from the company
Restricted Share Units
+16,69216,692 directFiling · EDGAR
Apr 1, 2022Option or RSU exercised or converted
Restricted Share Units
−1,0604,240 directFiling · EDGAR
Dec 1, 2021Shares withheld for tax or exercise price−2,075$71.23$148K27,925 directFiling · EDGAR
Apr 1, 2021Grant or award from the company
Stock Options (Right to Buy)
+28,00028,000 directFiling · EDGAR
Apr 1, 2021Grant or award from the company
Restricted Share Units
+5,3005,300 directFiling · EDGAR
All 26 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Oct 1, 2026Form 4Revolution Medicines RVMDFiling · EDGAR
Sep 29, 2026Form 144Revolution Medicines RVMDFiling · EDGAR
Sep 18, 2026Form 4Revolution Medicines RVMDFiling · EDGAR
Sep 15, 2026Form 144Revolution Medicines RVMDFiling · EDGAR
Mar 26, 2026Form 3Revolution Medicines RVMDFiling · EDGAR
Jan 21, 2026Form 4Alx Oncology Holdings ALXOFiling · EDGAR
Jul 24, 2025Form 4Elevation Oncology ELEVFiling · EDGAR
Jun 9, 2025Form 4Elevation Oncology ELEVFiling · EDGAR
Apr 15, 2025Form 4Alx Oncology Holdings ALXOFiling · EDGAR
Jan 23, 2025Form 4Alx Oncology Holdings ALXOFiling · EDGAR
Nov 19, 2024Form 4Alx Oncology Holdings ALXOFiling · EDGAR
Aug 7, 2024Form 4Alx Oncology Holdings ALXOFiling · EDGAR
Aug 7, 2024Form 3Alx Oncology Holdings ALXOFiling · EDGAR
Jun 17, 2024Form 4Elevation Oncology ELEVFiling · EDGAR
Mar 4, 2024Form 4Elevation Oncology ELEVFiling · EDGAR
Mar 4, 2024Form 3Elevation Oncology ELEVFiling · EDGAR
Jan 23, 2024Form 4Mirati TherapeuticsFiling · EDGAR
Jan 3, 2024Form 4Mirati TherapeuticsFiling · EDGAR
Aug 10, 2023Form 4Mirati TherapeuticsFiling · EDGAR
Nov 8, 2022Form 4Mirati TherapeuticsFiling · EDGAR
Nov 8, 2022Form 3Mirati TherapeuticsFiling · EDGAR
Jun 27, 2022Form 4Zai LabFiling · EDGAR
Apr 5, 2022Form 4Zai LabFiling · EDGAR
Dec 3, 2021Form 4Zai LabFiling · EDGAR
Apr 5, 2021Form 4Zai LabFiling · EDGAR
Jan 4, 2021Form 3Zai LabFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.